Associated Genetic Biomarkers
BCL2L11 is altered in 0.44% of all cancers with prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in BCL2L11 are BCL2L11 Mutation (0.28%), BCL2L11 Loss (0.07%), BCL2L11 R153W (0.02%), BCL2L11 Amplification (0.02%), and BCL2L11 E176K (0.01%) .
BCL2L11 status serves as an inclusion eligibility criteria in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials that contain BCL2L11 status as an inclusion criterion, 4 are phase 2 (4 open).
Trials with BCL2L11 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is BCL2L11 Deletion .
Carboplatin, gefitinib, afatinib, pemetrexed, and rivoceranib are the most frequent therapies in trials with BCL2L11 as an inclusion criteria .
Significance of BCL2L11 in Diseases
Non-Small Cell Lung Carcinoma +
BCL2L11 is altered in 0.34% of non-small cell lung carcinoma patients .
BCL2L11 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BCL2L11 status and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open) .
Squamous Cell Lung Carcinoma +
BCL2L11 is altered in 0.66% of squamous cell lung carcinoma patients .
BCL2L11 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2L11 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Lung Adenocarcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.